Precipio, Inc.

PRPO - Financial Snapshot

Healthcare sector | Diagnostics & Research industry

View on:
Ranks:

Metrics for PRPO

Price $23.19
Shares Outstanding 1.75M
Net Current Assets / Share $-0.99
netCurrentAssetsPerShare = (Current Assets - Total Liabilities) / Shares Outstanding
Net Tangible Assets / Share $1.48
netTangibleAssetsPerShare = (Total Assets - Intangibles - Total Liabilities) / Shares Outstanding
Max Earning Power / Share $1.99
maxEarningPowerPerShare = (EBITDA / EP_MULTIPLIER) / Shares Outstanding
Adjusted Earning Power $-0.43
adjustedEarningPower = (Net Income / EP_MULTIPLIER) / Shares Outstanding
Non-Cash Charges to Market Cap 1.04%
nonCashChargeToMKTCAP = Non-Cash Charges / Market Capitalization
Ave Max Earning Power (5Y) $0.00
Ave Max Earning Power (5Q Annualized) $4.05
Ave Max Earning Power Delta (5Q Ann - 5Y) $4.05
Net Cash / Share $0
cashValuePerShare = (Cash + Short Term Investments - Total Liabilities) / Shares Outstanding
Data as of: Price 12-18-25 16:00 ET, Balance Sheet 2025-09-30, Income Statement 2025-09-30, Cash Flow 2025-09-30

Indicators

Dividend indicators Value Date
Pays Dividend No 12-19-2025
Last Dividend Date 4-28-19
Income indicators Value Date
EBITDA Positive Yes 12-19-2025
Net Income Positive No 12-19-2025
Avg CA Burn (Annual %) -65.94% 12-19-2025
Avg CA Burn (Quarterly %) 12.00% 12-19-2025

Shares Outstanding Changes

Date Shares Outstanding Delta
2025-11-20 1,752,007 +132,423
2025-09-19 1,619,584 +4
2025-08-25 1,619,580 +107,570

Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.